Eloïse Laouenan Presents the Results of HEMOTHEPP-CHU Brest-GETBO Prospective Study
Eloïse Laouenan, PhD student in Life and Health Sciences, INSERM, shared on LinkedIn:
”Thanks to the CNGOF and the Pari(s) Santé Femmes congress for this opportunity to present the results of the epidemiology of VTE in the HEMOTHEPP/CHU Brest/GETBO prospective multicenter cohort study (20,238 unselected pregnant women included at delivery, followed 3 months).
Upcoming publication…
– High incidence of postpartum VTE
– Under-prescription of thromboprophylaxis
– Half of VTEs after 7 days postpartum
– High incidence in women at intermediate risk, with or without thromboprophylaxis
VTE risk assessment +++
Perspective: MUM-VTE CHU Brest/GETBO equals multicenter randomized controlled trial (F-CRIN INNOVTE) to evaluate the efficacy and safety of postpartum thromboprophylaxis in women at intermediate risk.
Thanks to all the patients and investigators.
Personal thanks to my team at Service de gynécologie obstétrique et médecine de la reproduction – CHU Brest !!!
Thanks for the photo and support!”
Stay updated with Hemostasis Today.
-
Mar 16, 2026, 07:26James Crowley, Professor of Medicine emeritus at Brown University, posted on LinkedIn:
-
Mar 15, 2026, 15:55Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 2
-
Mar 15, 2026, 14:09Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope
-
Mar 15, 2026, 14:02Denise M: Precision Hemostasis in Patient Blood Management
-
Mar 15, 2026, 13:57Abdulrahman Nasiri: D14 Bone Marrow Biopsy in AML Induction in the Era of Targeted Therapies
-
Mar 15, 2026, 13:52Valentin Ortiz-Maldonado: High-Impact Innovation in CAR-T Therapy Can Emerge From Academic Programmes
-
Mar 15, 2026, 13:45Tareq Abadl: Has Anyone Here Ever Taken an ALP Test Before?
-
Mar 14, 2026, 21:30Ayman Elbadawi: Why Does Stent Thrombosis Still Occur? Insights from the NCDR Data
-
Mar 14, 2026, 20:03Edward Adomako: Recognizing Thrombotic Thrombocytopenic Purpura as A Life-Threatening Emergency